公开(公告)号：US06265551B1

公开(公告)日：2001-07-24

申请号：US08657339

申请日：1996-06-03

Applicant: Jonathan S. Duke-Cohan ,  Chikao Morimoto ,  Stuart F. Schlossman

Inventor： Jonathan S. Duke-Cohan ,  Chikao Morimoto ,  Stuart F. Schlossman

IPC: C07K1600

CPC classification number: G01N33/573 ,  A61K38/00 ,  C07K16/40 ,  C12N9/48 ,  Y10S435/975

Abstract: A circulating, soluble form of DPPIV/CD26 isolated from human serum is disclosed. The serum form shares similar enzymatic and antigenic properties with the ubiquitous membrane form. However, in several biochemical aspects there are distinct differences. In particular, the circulating serum form has a molecular weight of 175 kDa (in contrast to the 105 kDa molecular weight of the membrane form), and it does not bind Adenosine Deaminase Type-1. Nevertheless, the circulating form expresses functional dipeptidylpeptidase IV activity and retains the ability to costimulate the T lymphocyte response to recall antigen. Circulating DPPIV has been determined to be the soluble form of a 175 kDa DPPIV CD26-related molecule rapidly expressed on the surface of activated T cells, prior to the expression of 105 kDa CD26. Although 105 kDa membrane type CD26 may be found in the serum in small amounts, the majority of serum DPPIV activity is provided by a novel peptidase structurally distinct from 105 kDa CD26/DPPIV. Polyclonal and monoclonal antibodies capable of distinguishing the 175 kDa form from the 105 kDa form are also disclosed.

Abstract translation: 公开了从人血清中分离的循环的可溶形式的DPPIV / CD26。 血清形式与普遍存在的膜形式具有相似的酶和抗原性质。 然而，在几个生化方面有明显的差异。 特别地，循环血清形式的分子量为175kDa（与膜形式的105kDa分子量相反），并且不结合腺苷脱氨酶1型。 然而，循环形式表达功能性二肽基肽酶IV活性，并保留共同刺激T淋巴细胞回忆抗原的能力。 循环DPPIV已被确定为在表达105kDa CD26之前在激活的T细胞表面上快速表达的175kDa DPPIV CD26相关分子的可溶形式。 尽管可以少量在血清中发现105kDa膜型CD26，但大部分血清DPPIV活性由与105kDa CD26 / DPPIV结构不同的新型肽酶提供。 还公开了能够区分175kDa形式与105kDa形式的多克隆和单克隆抗体。

公开(公告)号：US06933132B1

公开(公告)日：2005-08-23

申请号：US09787097

申请日：1999-09-14

Applicant: Jonathan S. Duke-Cohan ,  Stuart F. Schlossman

Inventor： Jonathan S. Duke-Cohan ,  Stuart F. Schlossman

IPC: A61K38/00 ,  C07H21/04 ,  C07K14/705 ,  C12N1/20 ,  C12N1/21 ,  C12N9/48 ,  C12N15/74 ,  C12N15/87 ,  C12P21/03

CPC classification number: C07K14/70596 ,  A61K38/00 ,  C12N9/48

Abstract: The invention features attracting polypeptides and nucleic acids encoding them. The attractin polypeptides are useful for enhancing immune responses.

Abstract translation: 本发明特征在于吸引编码它们的多肽和核酸。 吸引蛋白多肽可用于增强免疫应答。

公开(公告)号：US06325989B1

公开(公告)日：2001-12-04

申请号：US08457694

申请日：1995-06-01

Applicant: Jonathan S. Duke-Cohan ,  Chikao Morimoto ,  Stuart F. Schlossman

Inventor： Jonathan S. Duke-Cohan ,  Chikao Morimoto ,  Stuart F. Schlossman

IPC: A61B5055

Abstract: A soluble form of CD26 isolated from human serum is disclosed. The serum form shares similar enzymatic and antigenic properties with the membrane form. However, in several biochemical aspects there are distinct differences. In particular, the soluble serum form has a molecular weight of 175 kDa (in contrast to the 105 kDa molecular weight of the membrane form), and it does not bind Adenosine Deaminase Type-1. Nevertheless, the soluble form expresses functional dipeptidylpeptidase IV activity and retains the ability to costimulate the T lymphocyte response to recall antigen. Although 105 kDa membrane type CD26 may be found in the serum in small amounts, the majority of serum DPPIV activity is provided by a novel peptidase structurally distinct from membrane C26/DPPIV.

Abstract translation: 公开了从人血清中分离的可溶形式的CD26。 血清形式与膜形式具有相似的酶和抗原性质。 然而，在几个生化方面有明显的差异。 特别地，可溶性血清形式的分子量为175kDa（与膜形式的105kDa分子量相反），并且不结合腺苷脱氨酶1型。 然而，可溶形式表达功能性二肽基肽酶IV活性，并保留共同刺激T淋巴细胞回忆抗原的能力。 尽管少量血清中可以发现105kDa的膜型CD26，但大部分血清DPPIV活性由结构不同于膜C26 / DPPIV的新型肽酶提供。